Overall market sentiment has been high on PhaseBio Pharmaceuticals Inc (PHAS) stock lately. PHAS receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With PHAS Stock Today?
PhaseBio Pharmaceuticals Inc (PHAS) stock is trading at $3.86 as of 9:52 AM on Wednesday, Jun 9, a rise of $0.08, or 2.13% from the previous closing price of $3.78. The stock has traded between $3.80 and $4.00 so far today. Volume today is low. So far 15,886 shares have traded compared to average volume of 322,621 shares.
To see InvestorsObserver's Sentiment Score for PhaseBio Pharmaceuticals Inc click here.
More About PhaseBio Pharmaceuticals Inc
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Click Here to get the full Stock Score Report on PhaseBio Pharmaceuticals Inc (PHAS) Stock.
